Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash from Financing Activities (2020 - 2025)

Bioventus' Cash from Financing Activities history spans 6 years, with the latest figure at -$28.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 33.62% year-over-year to -$28.4 million; the TTM value through Dec 2025 reached -$62.1 million, down 13.85%, while the annual FY2025 figure was -$62.1 million, 13.85% down from the prior year.
  • Cash from Financing Activities reached -$28.4 million in Q4 2025 per BVS's latest filing, down from -$20.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $176.3 million in Q4 2021 to a low of -$62.2 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $9.6 million, with a median of -$2.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: soared 1884.86% in 2021, then crashed 306007.14% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $176.3 million in 2021, then tumbled by 103.08% to -$5.4 million in 2022, then skyrocketed by 99.74% to -$14000.0 in 2023, then plummeted by 306007.14% to -$42.9 million in 2024, then skyrocketed by 33.62% to -$28.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Cash from Financing Activities are -$28.4 million (Q4 2025), -$20.0 million (Q3 2025), and -$14.7 million (Q2 2025).